Effective
2001 and later
Reportable
for cases diagnosed
1978 and later
Primary Site(s)
C421
Primary site must be bone marrow (C421)
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010 see code 9861/3.)
Acute myeloid leukemia with MECOM rearrangement is part of the Acute myeloid leukemia (AML) lineage table in the WHO 5th edition of Hematolymphoid Tumors. (See Appendix B in the Hematopoietic Manual, Table B6)
Blood and bone marrow are always involved.
Patients with chronic myeloid leukemia (CML) may acquire MECOM rearrangement; such cases are defined as blast phase regardless of the number of blasts. Although rare, cases with concurrent BCR::ABL1 and MECOM rearrangement at presentation are best regarded as blast phase CML.
If this leukemia and myeloid sarcoma (9930/3) occur during the same clinical workup, this is one primary, the leukemia.
If the myeloid sarcoma occurs after the diagnosis of the leukemia, that is a manifestation of the leukemia and is the same primary.
See Multiple Primary Rule M3
Acute myeloid leukemia with MECOM rearrangement is part of the Acute myeloid leukemia (AML) lineage table in the WHO 5th edition of Hematolymphoid Tumors. (See Appendix B in the Hematopoietic Manual, Table B6)
Blood and bone marrow are always involved.
Patients with chronic myeloid leukemia (CML) may acquire MECOM rearrangement; such cases are defined as blast phase regardless of the number of blasts. Although rare, cases with concurrent BCR::ABL1 and MECOM rearrangement at presentation are best regarded as blast phase CML.
If this leukemia and myeloid sarcoma (9930/3) occur during the same clinical workup, this is one primary, the leukemia.
If the myeloid sarcoma occurs after the diagnosis of the leukemia, that is a manifestation of the leukemia and is the same primary.
See Multiple Primary Rule M3
Diagnostic Confirmation
This histology must be coded as diagnostic confirmation code 3 until the 2027 updates are implemented in your software. Once the software updates are implemented: Assign code 1 for histological confirmation WITH positive genetics
Module Rule
None
Alternate Names
Definition
Definitive Diagnostic Methods
Cytogenetics
Genetic testing
Genetics Data
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1; MECOM
Immunophenotyping
Not applicable, genetics required for diagnosis
Treatments
Hematologic Transplant and/or Endocrine Procedures
Transformations to
None
Transformations from
Same Primaries
Corresponding ICD-10 Codes (Cause of Death codes only)
C92.0 Acute myeloid leukemia
Corresponding ICD-10-CM Codes (U.S. only)
C92.0 Acute myeloblastic leukemia (effective October 01, 2015)
C92.00 Acute myeloblastic leukemia not having achieved remission (effective October 01, 2024)
C92.01 Acute myeloblastic leukemia, in remission (effective October 01, 2024)
C92.02 Acute myeloblastic leukemia, in remission (effective October 01, 2024)
Signs and Symptoms
Anemia
Easy bruising or bleeding
Fatigue
Fever
Petechiae
Shortness of breath
Splenomegaly
Thrombocytopenia
Weakness
Weight loss or loss of appetite
Diagnostic Exams
Progression and Transformation
None
Epidemiology and Mortality
Age: predominantly adults
Sex: no male or female predominance
Survival: aggressive neoplasm with short survival
Sources
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2024. (WHO classification of tumours series, 5th ed.; vol. 11). https://publications.iarc.who.int/637.
Section: Acute myeloid leukemia
Pages: Part A: 130-132
Section: Acute myeloid leukemia
Pages: Part A: 130-132
International Classification of Diseases for Oncology, 3rd edition (including revisions). Geneva: World Health Organization, 2001, 2011, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
PDQ® Adult Treatment Editorial Board. PDQ Acute Myeloid Leukemia Treatment. Bethesda, MD: National Cancer Institute. Updated <03/06/2024>. Available at: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq. Accessed <02/06/2025>. [PMID: 26389432]
Section: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
Section: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
Home